Zynerba Pharmaceuticals, Inc. logo

ZYNE

Zynerba Pharmaceuticals, Inc.

$0.58

Earnings Summary

Net Profits
$-8.68Mn

Highlights

Net Profits:

Zynerba Pharmaceuticals, Inc.’s net profit jumped 18.01% since last year same period to $-8.68Mn in the Q3 2022. On a quarterly growth basis, Zynerba Pharmaceuticals, Inc. has generated 11.94% jump in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Zynerba Pharmaceuticals, Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-0.23
EPS Estimate Current Year
-0.23

Highlights

EPS Estimate Current Quarter:

Zynerba Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.23 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

Zynerba Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.23.

Key Ratios

Key ratios of the Zynerba Pharmaceuticals, Inc. post its Q2 2022 earnings

Earning Per Share (EPS)
-0.24
Return on Assets (ROA)
-0.29
Return on Equity (ROE)
-0.55

Highlights

Earning Per Share (EPS):

Zynerba Pharmaceuticals, Inc.’s earning per share (EPS) jumped 4% since last year same period to -0.24 in the Q2 2022. This indicates that the Zynerba Pharmaceuticals, Inc. has generated 4% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Zynerba Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.29.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Zynerba Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.55.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-16
-0.23
-0.21
7.89%
2022-08-10
-0.23
-0.24
-4.35%

Company Information

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies.

Organisation
Zynerba Pharmaceuticals, Inc.
Headquarters
80 West Lancaster Avenue, Devon, PA, United States, 19333
Employees
28
Industry
Health Technology
CEO
Armando Anido

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*